Efficacy of Vortioxetine on Anhedonia: Results from a Pooled Analysis of Short-Term Studies in Patients with Major Depressive Disorder

Roger S McIntyre,1 Henrik Loft,2 Michael Cronquist Christensen3 1Mood Disorders Psychopharmacology Unit, University Health Network, University of Toronto, Toronto, ON, Canada; 2Department of Biostatistics and Programming, H. Lundbeck A/S, Valby, Denmark; 3Department of Psychiatry Products, H. Lundbe...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	McIntyre RS, Loft H, Christensen MC
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	anhedonia functioning major depressive disorder vortioxetine Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/0f54be31881b4241a9bec6cb7ab060e1
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:0f54be31881b4241a9bec6cb7ab060e1
record_format	dspace
spelling	oai:doaj.org-article:0f54be31881b4241a9bec6cb7ab060e12021-12-02T10:59:34ZEfficacy of Vortioxetine on Anhedonia: Results from a Pooled Analysis of Short-Term Studies in Patients with Major Depressive Disorder1178-2021https://doaj.org/article/0f54be31881b4241a9bec6cb7ab060e12021-02-01T00:00:00Zhttps://www.dovepress.com/efficacy-of-vortioxetine-on-anhedonia-results-from-a-pooled-analysis-o-peer-reviewed-article-NDThttps://doaj.org/toc/1178-2021Roger S McIntyre,1 Henrik Loft,2 Michael Cronquist Christensen3 1Mood Disorders Psychopharmacology Unit, University Health Network, University of Toronto, Toronto, ON, Canada; 2Department of Biostatistics and Programming, H. Lundbeck A/S, Valby, Denmark; 3Department of Psychiatry Products, H. Lundbeck A/S, Valby, DenmarkCorrespondence: Michael Cronquist ChristensenH. Lundbeck A/S, Ottiliavej 9, 2500 Valby, DenmarkTel +45 30835168Email MCRC@lundbeck.comPurpose: Anhedonia is a core symptom of major depressive disorder (MDD), which has important functional consequences for the patient. This post hoc analysis investigated the relationship between anhedonia and functioning in patients with MDD treated with vortioxetine.Patients and Methods: We conducted a pooled analysis of all 11 short-term, double-blind, randomized, placebo-controlled studies of vortioxetine (fixed dose, 5– 20 mg/day) in patients with MDD which included Montgomery–Åsberg Depression Rating Scale (MADRS) and Sheehan Disability Scale (SDS) assessments. A short-term, randomized, active-controlled trial of flexible-dose treatment with vortioxetine (10– 20 mg/day) versus agomelatine (25– 50 mg/day) was also analyzed. Mean changes from baseline to study endpoint in MADRS total, MADRS anhedonia subscale, SDS total, and SDS social-functioning scores were analyzed by a mixed model for repeated measures. The relationship between treatment effects on anhedonia and functioning was investigated using path analysis.Results: A total of 4988 patients with MDD were included in the placebo-controlled studies and 495 in the active-comparator study. Significant dose-dependent improvements in overall depressive symptoms, anhedonia, and measures of functioning were seen in vortioxetine-treated patients compared with those who received placebo or agomelatine. Results of the path analysis for the placebo-controlled studies suggested that the effect on functioning was mostly driven by the effect of treatment on MADRS anhedonia factors.Conclusion: Vortioxetine showed significant short-term efficacy against anhedonia in this large population of patients with MDD. In the placebo-controlled studies, improvements in functioning associated with vortioxetine appeared to be mostly driven by the effect of treatment on MADRS anhedonia factors.Keywords: anhedonia, functioning, major depressive disorder, vortioxetineMcIntyre RSLoft HChristensen MCDove Medical Pressarticleanhedoniafunctioningmajor depressive disordervortioxetineNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol Volume 17, Pp 575-585 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	anhedonia functioning major depressive disorder vortioxetine Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	anhedonia functioning major depressive disorder vortioxetine Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 McIntyre RS Loft H Christensen MC Efficacy of Vortioxetine on Anhedonia: Results from a Pooled Analysis of Short-Term Studies in Patients with Major Depressive Disorder
description	Roger S McIntyre,1 Henrik Loft,2 Michael Cronquist Christensen3 1Mood Disorders Psychopharmacology Unit, University Health Network, University of Toronto, Toronto, ON, Canada; 2Department of Biostatistics and Programming, H. Lundbeck A/S, Valby, Denmark; 3Department of Psychiatry Products, H. Lundbeck A/S, Valby, DenmarkCorrespondence: Michael Cronquist ChristensenH. Lundbeck A/S, Ottiliavej 9, 2500 Valby, DenmarkTel +45 30835168Email MCRC@lundbeck.comPurpose: Anhedonia is a core symptom of major depressive disorder (MDD), which has important functional consequences for the patient. This post hoc analysis investigated the relationship between anhedonia and functioning in patients with MDD treated with vortioxetine.Patients and Methods: We conducted a pooled analysis of all 11 short-term, double-blind, randomized, placebo-controlled studies of vortioxetine (fixed dose, 5– 20 mg/day) in patients with MDD which included Montgomery–Åsberg Depression Rating Scale (MADRS) and Sheehan Disability Scale (SDS) assessments. A short-term, randomized, active-controlled trial of flexible-dose treatment with vortioxetine (10– 20 mg/day) versus agomelatine (25– 50 mg/day) was also analyzed. Mean changes from baseline to study endpoint in MADRS total, MADRS anhedonia subscale, SDS total, and SDS social-functioning scores were analyzed by a mixed model for repeated measures. The relationship between treatment effects on anhedonia and functioning was investigated using path analysis.Results: A total of 4988 patients with MDD were included in the placebo-controlled studies and 495 in the active-comparator study. Significant dose-dependent improvements in overall depressive symptoms, anhedonia, and measures of functioning were seen in vortioxetine-treated patients compared with those who received placebo or agomelatine. Results of the path analysis for the placebo-controlled studies suggested that the effect on functioning was mostly driven by the effect of treatment on MADRS anhedonia factors.Conclusion: Vortioxetine showed significant short-term efficacy against anhedonia in this large population of patients with MDD. In the placebo-controlled studies, improvements in functioning associated with vortioxetine appeared to be mostly driven by the effect of treatment on MADRS anhedonia factors.Keywords: anhedonia, functioning, major depressive disorder, vortioxetine
format	article
author	McIntyre RS Loft H Christensen MC
author_facet	McIntyre RS Loft H Christensen MC
author_sort	McIntyre RS
title	Efficacy of Vortioxetine on Anhedonia: Results from a Pooled Analysis of Short-Term Studies in Patients with Major Depressive Disorder
title_short	Efficacy of Vortioxetine on Anhedonia: Results from a Pooled Analysis of Short-Term Studies in Patients with Major Depressive Disorder
title_full	Efficacy of Vortioxetine on Anhedonia: Results from a Pooled Analysis of Short-Term Studies in Patients with Major Depressive Disorder
title_fullStr	Efficacy of Vortioxetine on Anhedonia: Results from a Pooled Analysis of Short-Term Studies in Patients with Major Depressive Disorder
title_full_unstemmed	Efficacy of Vortioxetine on Anhedonia: Results from a Pooled Analysis of Short-Term Studies in Patients with Major Depressive Disorder
title_sort	efficacy of vortioxetine on anhedonia: results from a pooled analysis of short-term studies in patients with major depressive disorder
publisher	Dove Medical Press
publishDate	2021
url	https://doaj.org/article/0f54be31881b4241a9bec6cb7ab060e1
work_keys_str_mv	AT mcintyrers efficacyofvortioxetineonanhedoniaresultsfromapooledanalysisofshorttermstudiesinpatientswithmajordepressivedisorder AT lofth efficacyofvortioxetineonanhedoniaresultsfromapooledanalysisofshorttermstudiesinpatientswithmajordepressivedisorder AT christensenmc efficacyofvortioxetineonanhedoniaresultsfromapooledanalysisofshorttermstudiesinpatientswithmajordepressivedisorder
_version_	1718396337412636672

Efficacy of Vortioxetine on Anhedonia: Results from a Pooled Analysis of Short-Term Studies in Patients with Major Depressive Disorder

Ejemplares similares